Company profile: March Therapeutics
1.1 - Company Overview
Company description
- Provider of genome-based services leveraging proprietary molecular recording technologies and advanced computing to discover and optimize therapeutic enzymes. Offers ultra-high-throughput mapping of protein sequence to function, generating scalable sequence-based datasets to accelerate therapeutic development.
Products and services
- Biomolecular Learning: An evolutionary system that integrates molecular recording and advanced computing to discover and optimize enzymes for therapeutic applications
- Genome-Based Services: Delivers therapeutic-focused services that leverage molecular recording and advanced computing to build sequence-to-function mappings and enable enzyme discovery and optimization
- Molecular Recording Technologies: Proprietary technologies that enable ultra-high-throughput mapping of protein sequence to function, creating scalable sequence-based datasets for therapeutic development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to March Therapeutics
Horizon Discovery
HQ: United Kingdom
Website
- Description: Provider of gene editing and gene modulation platforms and services, including the Pin-point Base Editing Platform for precise base changes, Dharmacon siRNA, shRNA, and CRISPR reagents, drug discovery screening services, pre-engineered cell lines, and Mimix cell line-derived molecular reference standards for research and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Horizon Discovery company profile →
Centogene
HQ: Germany
Website
- Description: Provider of methods and technology for human genetics analysis, delivering genetic diagnostic analyses of rare inherited diseases and transforming global genetic data into medical decisions to create broader awareness for patients of all ethnicities around the world.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centogene company profile →
MIDI
HQ: United States
Website
- Description: Provider of chemical analysis and microbial identification solutions for agriculture and environmental microbiology laboratories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MIDI company profile →
InVivo Biotech Services
HQ: Germany
Website
- Description: Provider of contract manufacturing services for development and production of monoclonal antibodies and recombinant proteins. Offerings include antibody production from hybridomas (small to large scale), recombinant protein expression in bacterial and mammalian systems, non-GMP cell line development, research antibodies produced in HEK under serum-free conditions, and SARS‑CoV‑2 antigens and antibodies for immunoassays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InVivo Biotech Services company profile →
NeoPhore
HQ: United Kingdom
Website
- Description: Provider of novel small molecule cancer therapies that stimulate the immune system by targeting DNA mismatch repair to induce neoantigen expression and increase immunogenicity in solid tumors, including PMS2 and MLH1 modulators that convert immune-cold tumors to hot and enhance sensitivity to immune checkpoint inhibitors, plus continuous neoantigen creation and research and development on next-generation targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoPhore company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for March Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to March Therapeutics
2.2 - Growth funds investing in similar companies to March Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for March Therapeutics
4.2 - Public trading comparable groups for March Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →